commercialization news from FierceBiotech
News
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
EUSA Pharma spins off assets as it narrows focus
The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and Read more...
Vernalis inks financing deal
Vernalis has signed a €18.4M financing agreement with Paul Capital Healthcare for frovatriptan, Vernalis' migraine drug. In return for the cash, Paul Capital Healthcare will receive Read more...
Cash-hungry Thallion hunts for development partner
Thallion Pharmaceuticals is hunting for a partner to help with its development of Shigamabs, a therapy for E. coli food borne bacterial infections. The biotech says it will also delay its Phase Read more...
Arena touts safety profile of obesity drug
The analysts were buzzing this morning about Arena Pharmaceuticals' chances of a major partnership pact for its obesity drug Read more...
EUSA raises $50M to help fund Cytogen buyout
About four months after launching a review of its strategic alternatives, Cytogen has landed in the arms of EUSA, Read more...
Dr. Reddy's joins with 7TM on research pact
India's Dr. Reddy's Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Both companies agreed to collaborate on selecting new drug candidates, jointly advancing them Read more...
Sanofi to pay $500M for Dyax antibody program
Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal Read more...
Viventia considers sale/merger in strategic review
Viventia Biotech is also going the way of the strategic review, promising to consider its sale or merger options as it advances new antibody therapies for cancer. HSBC has been brought in to advise Read more...
SPOTLIGHT: Exelixis gains $35M milestone payment from GSK
GSK has exercised its option to exclusively license Exelixis' XL880 for further development. Exelixis gains a milestone payment of $35 million, as well as additional payments upon the attainment of Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight